Kalaris Therapeutics (KLRS) Total Liabilities (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Total Liabilities of $41.2 million for Q1 2026, up 5.18% year-over-year from $39.2 million in Q1 2025, and down 3.9% quarter-over-quarter from $42.9 million in Q4 2025.
Kalaris Therapeutics (KLRS) Total Liabilities (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $41.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 5.18% year-over-year to $41.2 million; the TTM figure through Mar 2026 stood at $41.2 million (up 5.18% YoY), while the FY2025 annual figure was $42.9 million, down 24.41% from the prior year.
- Total Liabilities for Q1 2026 stood at $41.2 million, down from $42.9 million in the prior quarter.
- The five-year high for Total Liabilities was $56.8 million in Q4 2024, with the low at $1.4 million in Q3 2024.
- The 5-year median for Total Liabilities is $41.2 million (2026), against an average of $39.5 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities tumbled 97.33% in 2024, then soared 2683.99% in 2025.
- Kalaris Therapeutics' Total Liabilities stood at $52.6 million in 2022, then decreased by 14.36% to $45.0 million in 2023, then advanced by 26.13% to $56.8 million in 2024, then declined by 24.41% to $42.9 million in 2025, then decreased by 3.9% to $41.2 million in 2026.
- Business Quant data shows KLRS's Total Liabilities at $41.2 million in Q1 2026, $42.9 million in Q4 2025, and $39.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 10.03 Bn |
| 10 | Kalaris Therapeutics | 99.71 Mn | 99.71 Mn | - | 41.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.87 Mn |
| Mar 31, 2026 | 41.25 Mn |
| Dec 31, 2025 | 42.92 Mn |
| Sep 30, 2025 | 39.31 Mn |
| Jun 30, 2025 | 39.73 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 56.78 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 10.70 Mn |
| Mar 31, 2024 | 23.70 Mn |
| Dec 31, 2023 | 45.02 Mn |
| Sep 30, 2023 | 52.98 Mn |
| Jun 30, 2023 | 53.58 Mn |
| Mar 31, 2023 | 50.51 Mn |
| Dec 31, 2022 | 52.56 Mn |
| Sep 30, 2022 | 40.47 Mn |
| Jun 30, 2022 | 41.86 Mn |
| Mar 31, 2022 | 39.42 Mn |
| Dec 31, 2021 | 61.33 Mn |
| Sep 30, 2021 | 49.23 Mn |